ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study This double-blind, placebo-controlled, dose-finding study is designed to identify the lowest AGI-1067 dose that improves glycemic control as measured by HbA1c and fasting glucose in subjec...

• Country Bosnia and Herzegovina, Former Serbia and Montenegro, Georgia, India, Macedonia, the former Yugoslav Republic of, South Africa, Ukraine, United States
• organs None
• Specialty None

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attack...

• Country Czech Republic, Germany, Hungary, Israel, Italy, Macedonia, the former Yugoslav Republic of, Poland, Romania, Slovakia
• organs None
• Specialty None

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures us...

• Country Croatia, France, Hungary, Jordan, Kazakhstan, Lebanon, Macedonia, the former Yugoslav Republic of, Moldova, Republic of, Romania, Russian Federation, Ukraine
• organs None
• Specialty None

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes This trial is conducted in Asia, Europe and Oceania. The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to glimepiride compared to adding rosig...

• Country Australia, Croatia, India, Macedonia, the former Yugoslav Republic of, Philippines, Russian Federation, Turkey
• organs None
• Specialty None

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angi...

• Country Bulgaria, Canada, Hungary, Israel, Italy, Macedonia, the former Yugoslav Republic of, Poland, Romania, Serbia, South Africa, United States
• organs None
• Specialty None

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia This study consists of a 4 week run-in period with a Ca based phosphate binder and 12 weeks treatment period by MCI-196 or placebo, (both on Ca based phosphate binder). During the treatmen...

• Country Czech Republic, France, Germany, Italy, Macedonia, the former Yugoslav Republic of, Poland, Serbia, South Africa, Spain, United Kingdom
• organs None
• Specialty None

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised,...

• Country Hungary, Italy, Macedonia, the former Yugoslav Republic of, Malaysia, Poland, Russian Federation, Serbia, Ukraine
• organs None
• Specialty None